NeuroPace Falls 37% on Nov. 13 After Guidance Cut and Three Downgrades
NPCE traded between $5.46 and $7.71 in the Nov. 13 regular session on 5.79 million shares, against a 10-day average of 149,551. It closed far below its one-month low after a revenue miss and a lower 2026 forecast.

Neuropace, Inc. (NASDAQ: NPCE) reported third-quarter results after the close on Nov. 12, with revenue of $23.1 million, down 1.1% from a year earlier. The company cut its 2026 revenue guidance to $91 million to $92 million from $99.5 million to $101.5 million. Shares closed on Nov. 13 at $7.56, 37.1% below the prior close.
A one-day drop far outside the stock's recent range
From Oct. 15 to Nov. 12, NPCE's biggest daily gain was 8.37% and its biggest loss was 5.46%. On Nov. 13 the stock closed 37.1% below its Nov. 12 close, and every price traded that day, from the pre-market high of $8.40 to the regular-session low of $5.46, sat under the one-month low of $11.90 set on Nov. 12. The stock rebounded within the session and gave back part of that rebound after the close.
How the stock traded from Nov. 12 to Nov. 13
The slide began before the news. NPCE closed at $12.02 on Nov. 12, down 3.99% and its third straight lower close (after drops of 3.28% on Nov. 10 and 1.34% on Nov. 11). The company's 8-K filing landed at 4:07 p.m. ET, after that session had ended.
In after-hours trading on Nov. 12 (the session after the 4:00 p.m. close), shares fell 33.61% to $7.98. The last pre-market trade on Nov. 13, at 9:29 a.m. ET, was $6.25, or 48.0% below the Nov. 12 close. Pre-market volume was 110,696 shares, below the 10-day average of 149,551 shares for a full day, and the pre-market range ran from $6.14 to $8.40.
The regular session on Nov. 13 produced a low of $5.46 and a high of $7.71, and the stock closed at $7.56, near the top of that range. Volume was 5,785,820 shares, worth about $36.91 million. That equals about 21.5% of the 26.85 million-share float (the shares available to trade).
After-hours trading on Nov. 13 ended at $7.16, down 5.27% from the 4:00 p.m. close and 40.42% below the Nov. 12 close. Volume was 42,408 shares, in a range of $7.15 to $7.75.
Where the drop sits in the one-month path
From Oct. 15 through Nov. 12, NPCE fell 5.95% overall. The period high was $13.94 on Nov. 4, which was also the biggest up day, at 8.37%. The biggest down day was Oct. 30, at 5.46%. Closes in the final week of that span were $12.50 on Nov. 6, $13.12 on Nov. 9, $12.69 on Nov. 10, $12.52 on Nov. 11 and $12.02 on Nov. 12.
A revenue miss and a lower forecast arrived together
Estimates varied, but analysts had expected more than $27 million in third-quarter revenue, against the $23.1 million reported. Guidance is a company's own forecast for the year, and the new range sits below the old one.
Three firms cut their ratings on Nov. 13. Wells Fargo moved to Equal Weight from Overweight, and JPMorgan moved to Neutral from Overweight. Leerink Partners moved to Market Perform from Outperform and set a $7 price target. The 33.61% after-hours drop on Nov. 12 came before any of these changes.
The scale of the move also reflects how thinly the stock usually trades. Its 10-day average volume was 149,551 shares, and its float is 26.85 million shares.
What the quarter showed about the business
CEO Joel Becker said the shortfall was concentrated in several of the company's largest accounts and reflected account-level issues and changes to the field organization. He said scheduled fourth-quarter cases have begun to recover. Selected figures from the release:
- RNS System revenue (the company's epilepsy therapy) was $22.9 million, up 1.4% from the third quarter of 2025.
- The new full-year range represents underlying RNS growth of 10% to 11%, according to the company.
- Non-GAAP gross margin was 84.8%, versus 82.8% a year earlier.
- Net loss was $3.3 million, versus $4.9 million, and adjusted EBITDA was $0.4 million, versus a loss of $1.3 million.
- Cash, equivalents, short-term investments and restricted cash were $49.5 million at Sept. 30, versus $51.9 million at the end of the prior quarter. Long-term borrowings were $59.2 million.
The company also expects RNS growth of about 15% in 2027.
Regulatory milestones the company has laid out
- Around year end: the company expects to submit an amendment to its premarket approval supplement for idiopathic generalized epilepsy, after an October meeting with the FDA.
- Remote Care: the FDA submission has a planned 180-day review cycle.
- Early 2027: data collection for AURORA, a study meant to support an adolescent indication, is expected to finish, followed by analysis and an FDA submission.
Bottom line
NPCE closed 37.1% lower on Nov. 13 on volume far above its 10-day average, and no price traded that day reached the $11.90 one-month low. The stock bounced from its $5.46 low and slipped again after the close. Costs and losses improved in the quarter, but the stock fell on the revenue miss and the lower forecast.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




